

Gabriel N Hortobagyi

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4728720/gabriel-n-hortobagyi-publications-by-year.pdf>

Version: 2024-04-18

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

325
papers

36,178
citations

86
h-index

186
g-index

339
ext. papers

41,439
ext. citations

9.1
avg, IF

6.84
L-index

#	Paper	IF	Citations
325	Abstract GS2-01: Overall survival subgroup analysis by metastatic site from the phase 3 MONALEESA-2 study of first-line ribociclib + letrozole in postmenopausal patients with advanced HR+/HER2- breast cancer. <i>Cancer Research</i> , 2022 , 82, GS2-01-GS2-01	10.1	0
324	Reply to A. Pfob and C. Sidey-Gibbons.. <i>JCO Clinical Cancer Informatics</i> , 2022 , 6, e2100171	5.2	
323	Abstract PD2-05: Genomic profiling of PAM50-based intrinsic subtypes in HR+/HER2- advanced breast cancer (ABC) across the MONALEESA (ML) studies. <i>Cancer Research</i> , 2022 , 82, PD2-05-PD2-05	10.1	0
322	Overall Survival with Ribociclib plus Letrozole in Advanced Breast Cancer.. <i>New England Journal of Medicine</i> , 2022 , 386, 942-950	59.2	18
321	Invasive lobular carcinoma: an understudied emergent subtype of breast cancer.. <i>Breast Cancer Research and Treatment</i> , 2022 , 1	4.4	2
320	Ephrin receptor A10 monoclonal antibodies and the derived chimeric antigen receptor T cells exert an antitumor response in mouse models of triple-negative breast cancer.. <i>Journal of Biological Chemistry</i> , 2022 , 101817	5.4	2
319	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer.. <i>New England Journal of Medicine</i> , 2021 , 385, 2336-2347	59.2	45
318	Estrogen Receptor: A Paradigm for Targeted Therapy. <i>Cancer Research</i> , 2021 , 81, 5396-5398	10.1	
317	Inflammatory breast cancer: early recognition and diagnosis is critical. <i>American Journal of Obstetrics and Gynecology</i> , 2021 , 225, 392-396	6.4	2
316	TYRO3 induces anti-PD-1/PD-L1 therapy resistance by limiting innate immunity and tumoral ferroptosis. <i>Journal of Clinical Investigation</i> , 2021 , 131,	15.9	20
315	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021 ,	9.7	1
314	Human ribonuclease 1 serves as a secretory ligand of ephrin A4 receptor and induces breast tumor initiation. <i>Nature Communications</i> , 2021 , 12, 2788	17.4	3
313	Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors. <i>Clinical Cancer Research</i> , 2021 ,	12.9	1
312	Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer. <i>ELife</i> , 2021 , 10,	8.9	4
311	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021 , 39, 3938-3958	2.2	11
310	Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2021 ,	12.9	5
309	Physical Activity Before, During, and After Chemotherapy for High-Risk Breast Cancer: Relationships With Survival. <i>Journal of the National Cancer Institute</i> , 2021 , 113, 54-63	9.7	40

308	Risk factors for bisphosphonate-associated osteonecrosis of the jaw in the prospective randomized trial of adjuvant bisphosphonates for early-stage breast cancer (SWOG 0307). <i>Supportive Care in Cancer</i> , 2021 , 29, 2509-2517	3.9	7
307	Prognostic Model for De Novo and Recurrent Metastatic Breast Cancer. <i>JCO Clinical Cancer Informatics</i> , 2021 , 5, 789-804	5.2	4
306	Evaluating Serum Thymidine Kinase 1 in Patients with Hormone Receptor-Positive Metastatic Breast Cancer Receiving First-line Endocrine Therapy in the SWOG S0226 Trial. <i>Clinical Cancer Research</i> , 2021 , 27, 6115-6123	12.9	2
305	Impact of Delayed Neoadjuvant Systemic Chemotherapy on Overall Survival Among Patients with Breast Cancer. <i>Oncologist</i> , 2020 , 25, 749-757	5.7	8
304	Incorporation of clinical and biological factors improves prognostication and reflects contemporary clinical practice. <i>Npj Breast Cancer</i> , 2020 , 6, 11	7.8	1
303	Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer. <i>American Journal of Cancer Research</i> , 2020 , 10, 648-661	4.4	15
302	Phase III Randomized Trial of Bisphosphonates as Adjuvant Therapy in Breast Cancer: S0307. <i>Journal of the National Cancer Institute</i> , 2020 , 112, 698-707	9.7	22
301	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020 , 6, 505-511	13.4	27
300	Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. <i>Cancer Medicine</i> , 2020 , 9, 1025-1032	4.8	11
299	Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). <i>Journal of Clinical Oncology</i> , 2020 , 38, 804-814	2.2	64
298	Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 597-609	59.2	396
297	Bernard Fisher: A Pioneer Moves On. <i>Oncologist</i> , 2020 , 25, 89-90	5.7	1
296	Cancer Cell Metabolism Bolsters Immunotherapy Resistance by Promoting an Immunosuppressive Tumor Microenvironment. <i>Frontiers in Oncology</i> , 2020 , 10, 1197	5.3	15
295	Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 7388-7395	12.9	2
294	Oncogenic lncRNA downregulates cancer cell antigen presentation and intrinsic tumor suppression. <i>Nature Immunology</i> , 2019 , 20, 835-851	19.1	147
293	Overall Survival with Fulvestrant plus Anastrozole in Metastatic Breast Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 1226-1234	59.2	65
292	Efficacy and Safety of Ribociclib With Letrozole in US Patients Enrolled in the MONALEESA-2 Study. <i>Clinical Breast Cancer</i> , 2019 , 19, 268-277.e1	3	6
291	Leptomeningeal carcinomatosis in patients with breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2019 , 135, 85-94	7	46

290	Removal of N-Linked Glycosylation Enhances PD-L1 Detection and Predicts Anti-PD-1/PD-L1 Therapeutic Efficacy. <i>Cancer Cell</i> , 2019 , 36, 168-178.e4	24.3	124
289	Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation. <i>Breast Cancer Research</i> , 2019 , 21, 78	8.3	75
288	CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer. <i>Nature Communications</i> , 2019 , 10, 5114	17.4	32
287	John Mendelsohn: A visionary scientist, oncologist and leader. <i>Genes and Cancer</i> , 2019 , 10, 109-118	2.9	2
286	Synergism of PARP inhibitor fluzoparib (HS10160) and MET inhibitor HS10241 in breast and ovarian cancer cells. <i>American Journal of Cancer Research</i> , 2019 , 9, 608-618	4.4	12
285	New and important changes in breast cancer TNM: incorporation of biologic factors into staging. <i>Expert Review of Anticancer Therapy</i> , 2019 , 19, 309-318	3.5	4
284	Circulating Tumor Cell Clusters in Patients with Metastatic Breast Cancer: a SWOG S0500 Translational Medicine Study. <i>Clinical Cancer Research</i> , 2019 , 25, 6089-6097	12.9	27
283	Efficacy and safety of the combination of metformin, everolimus and exemestane in overweight and obese postmenopausal patients with metastatic, hormone receptor-positive, HER2-negative breast cancer: a phase II study. <i>Investigational New Drugs</i> , 2019 , 37, 345-351	4.3	20
282	Indirect Evaluation of Bone Saturation with Zoledronic Acid After Long-Term Dosing. <i>Oncologist</i> , 2019 , 24, 178-184	5.7	3
281	Development of CNS metastases and survival in patients with inflammatory breast cancer. <i>Cancer</i> , 2018 , 124, 2299-2305	6.4	6
280	A phase II study of tipifarnib and gemcitabine in metastatic breast cancer. <i>Investigational New Drugs</i> , 2018 , 36, 299-306	4.3	11
279	Characterization of bone only metastasis patients with respect to tumor subtypes. <i>Npj Breast Cancer</i> , 2018 , 4, 2	7.8	21
278	Eradication of Triple-Negative Breast Cancer Cells by Targeting Glycosylated PD-L1. <i>Cancer Cell</i> , 2018 , 33, 187-201.e10	24.3	230
277	Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018. <i>Current Breast Cancer Reports</i> , 2018 , 10, 296-306	0.8	4
276	Prognostic Factors in Patients with Metastatic Breast Cancer with Bone-Only Metastases. <i>Oncologist</i> , 2018 , 23, 1282-1288	5.7	29
275	Comparative Effectiveness of an mTOR-Based Systemic Therapy Regimen in Advanced, Metaplastic and Nonmetaplastic Triple-Negative Breast Cancer. <i>Oncologist</i> , 2018 , 23, 1300-1309	5.7	28
274	Ribociclib plus letrozole versus letrozole alone in patients with de novo HR+, HER2- advanced breast cancer in the randomized MONALEESA-2 trial. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 127-134	4.4	62
273	Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer-Reply. <i>JAMA Oncology</i> , 2018 , 4, 586	13.4	1

272	Validation Study of the American Joint Committee on Cancer Eighth Edition Prognostic Stage Compared With the Anatomic Stage in Breast Cancer. <i>JAMA Oncology</i> , 2018 , 4, 203-209	13.4	110
271	New and Important Changes in the TNM Staging System for Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018 , 38, 457-467	7.1	37
270	American Society of Clinical Oncology® Global Oncology Leadership Task Force: Findings and Actions. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	7
269	A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR- β <i>Investigational New Drugs</i> , 2018 , 36, 1103-1109	4.3	9
268	Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial. <i>Breast Cancer Research</i> , 2018 , 20, 123	8.3	24
267	Ribociclib for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 289	59.2	12
266	Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1049-1060	2.2	288
265	Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. <i>JAMA Oncology</i> , 2017 , 3, 906-912	13.4	97
264	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. <i>Clinical Cancer Research</i> , 2017 , 23, 3711-3720	12.9	460
263	Correlation between PIK3CA mutations in cell-free DNA and everolimus efficacy in HR, HER2 advanced breast cancer: results from BOLERO-2. <i>British Journal of Cancer</i> , 2017 , 116, 726-730	8.7	82
262	Poor prognosis of patients with triple-negative breast cancer can be stratified by RANK and RANKL dual expression. <i>Breast Cancer Research and Treatment</i> , 2017 , 164, 57-67	4.4	19
261	Personalized Prognostic Prediction Models for Breast Cancer Recurrence and Survival Incorporating Multidimensional Data. <i>Journal of the National Cancer Institute</i> , 2017 , 109,	9.7	23
260	Inflammatory breast cancer: a proposed conceptual shift in the UICC-AJCC TNM staging system. <i>Lancet Oncology</i> , <i>The</i> , 2017 , 18, e228-e232	21.7	54
259	Breast Cancer-Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. <i>Ca-A Cancer Journal for Clinicians</i> , 2017 , 67, 290-303	220.7	422
258	Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. <i>Journal of Cancer</i> , 2017 , 8, 1045-1052	4.5	7
257	Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 2991-3002	12.9	33
256	Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 35656-35668	3.3	32
255	EGFR signaling promotes inflammation and cancer stem-like activity in inflammatory breast cancer. <i>Oncotarget</i> , 2017 , 8, 67904-67917	3.3	24

254	Reverse phase protein array identification of triple-negative breast cancer subtypes and comparison with mRNA molecular subtypes. <i>Oncotarget</i> , 2017 , 8, 70481-70495	3.3	10
253	Prevalence of ESR1 Mutations in Cell-Free DNA and Outcomes in Metastatic Breast Cancer: A Secondary Analysis of the BOLERO-2 Clinical Trial. <i>JAMA Oncology</i> , 2016 , 2, 1310-1315	13.4	285
252	Glycosylation and stabilization of programmed death ligand-1 suppresses T-cell activity. <i>Nature Communications</i> , 2016 , 7, 12632	17.4	408
251	Deubiquitination and Stabilization of PD-L1 by CSN5. <i>Cancer Cell</i> , 2016 , 30, 925-939	24.3	332
250	Towards a transcriptome-based theranostic platform for unfavorable breast cancer phenotypes. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016 , 113, 12780-12785	11.5	27
249	Phase I biomarker modulation study of atorvastatin in women at increased risk for breast cancer. <i>Breast Cancer Research and Treatment</i> , 2016 , 158, 67-77	4.4	14
248	Incidence of Atypical Femur Fractures in Cancer Patients: The MD Anderson Cancer Center Experience. <i>Journal of Bone and Mineral Research</i> , 2016 , 31, 1569-76	6.3	36
247	AKT1 Inhibits Epithelial-to-Mesenchymal Transition in Breast Cancer through Phosphorylation-Dependent Twist1 Degradation. <i>Cancer Research</i> , 2016 , 76, 1451-62	10.1	58
246	EGFR Signaling Enhances Aerobic Glycolysis in Triple-Negative Breast Cancer Cells to Promote Tumor Growth and Immune Escape. <i>Cancer Research</i> , 2016 , 76, 1284-96	10.1	141
245	Blocking c-Met-mediated PARP1 phosphorylation enhances anti-tumor effects of PARP inhibitors. <i>Nature Medicine</i> , 2016 , 22, 194-201	50.5	141
244	The American Society of Clinical Oncology® Efforts to Support Global Cancer Medicine. <i>Journal of Clinical Oncology</i> , 2016 , 34, 76-82	2.2	10
243	The Neo-Bioscore Update for Staging Breast Cancer Treated With Neoadjuvant Chemotherapy: Incorporation of Prognostic Biologic Factors Into Staging After Treatment. <i>JAMA Oncology</i> , 2016 , 2, 929-36	13.4	73
242	Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy. <i>JAMA Oncology</i> , 2016 , 2, 508-16	13.4	70
241	Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. <i>Journal of Clinical Oncology</i> , 2016 , 34, 419-26	2.2	154
240	The Association between EGFR and cMET Expression and Phosphorylation and Its Prognostic Implication in Patients with Breast Cancer. <i>PLoS ONE</i> , 2016 , 11, e0152585	3.7	14
239	Current challenges of metastatic breast cancer. <i>Cancer and Metastasis Reviews</i> , 2016 , 35, 495-514	9.6	42
238	High HER2/Centromeric Probe for Chromosome 17 Fluorescence In Situ Hybridization Ratio Predicts Pathologic Complete Response and Survival Outcome in Patients Receiving Neoadjuvant Systemic Therapy With Trastuzumab for HER2-Overexpressing Locally Advanced Breast Cancer. <i>Oncologist</i> , 2016 , 21, 21-7	5.7	9
237	Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1738-1748	59.2	975

236	Circulating tumor cells in newly diagnosed inflammatory breast cancer. <i>Breast Cancer Research</i> , 2015 , 17, 2	8.3	33
235	Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 458-66	3	9
234	Acute and Short-term Toxic Effects of Conventionally Fractionated vs Hypofractionated Whole-Breast Irradiation: A Randomized Clinical Trial. <i>JAMA Oncology</i> , 2015 , 1, 931-41	13.4	154
233	BRCAPRO 6.0 Model Validation in Male Patients Presenting for BRCA Testing. <i>Oncologist</i> , 2015 , 20, 593-7	3.7	9
232	Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2. <i>Neoplasia</i> , 2015 , 17, 279-88	6.4	43
231	Receptor status change from primary to residual breast cancer after neoadjuvant chemotherapy and analysis of survival outcomes. <i>Clinical Breast Cancer</i> , 2015 , 15, 153-60	3	27
230	Antitumor Activity of KW-2450 against Triple-Negative Breast Cancer by Inhibiting Aurora A and B Kinases. <i>Molecular Cancer Therapeutics</i> , 2015 , 14, 2687-99	6.1	10
229	Comparison of cardiac events associated with liposomal doxorubicin, epirubicin and doxorubicin in breast cancer: a Bayesian network meta-analysis. <i>European Journal of Cancer</i> , 2015 , 51, 2314-20	7.5	33
228	SWOG S0221: a phase III trial comparing chemotherapy schedules in high-risk early-stage breast cancer. <i>Journal of Clinical Oncology</i> , 2015 , 33, 58-64	2.2	72
227	Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer. <i>Journal of Cancer</i> , 2015 , 6, 310-8	4.5	14
226	Phase II Randomized Study of Ixabepilone Versus Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2015 , 15, 325-31	3	15
225	The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells. <i>International Journal of Oncology</i> , 2015 , 47, 262-8	4.4	49
224	Phase III trial of bisphosphonates as adjuvant therapy in primary breast cancer: SWOG/Alliance/ECOG-ACRIN/NCIC Clinical Trials Group/NRG Oncology study S0307.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 503-503	2.2	14
223	Functional consequence of the MET-T1010I polymorphism in breast cancer. <i>Oncotarget</i> , 2015 , 6, 2604-14	3.3	27
222	Phosphorylation of EZH2 at T416 by CDK2 contributes to the malignancy of triple negative breast cancers. <i>American Journal of Translational Research (discontinued)</i> , 2015 , 7, 1009-20	3	28
221	Effect of age and race on quality of life in young breast cancer survivors. <i>Clinical Breast Cancer</i> , 2014 , 14, e21-31	3	33
220	Everolimus plus exemestane as first-line therapy in HR+, HER2? advanced breast cancer in BOLERO-2. <i>Breast Cancer Research and Treatment</i> , 2014 , 143, 459-67	4.4	62
219	Simvastatin radiosensitizes differentiated and stem-like breast cancer cell lines and is associated with improved local control in inflammatory breast cancer patients treated with postmastectomy radiation. <i>Stem Cells Translational Medicine</i> , 2014 , 3, 849-56	6.9	51

218	Chemotherapy and targeted therapy for women with human epidermal growth factor receptor 2-negative (or unknown) advanced breast cancer: American Society of Clinical Oncology Clinical Practice Guideline. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3307-29	2.2	185
217	Circulating tumor cells and response to chemotherapy in metastatic breast cancer: SWOG S0500. <i>Journal of Clinical Oncology</i> , 2014 , 32, 3483-9	2.2	437
216	Definition of PKC- η CDK6, and MET as therapeutic targets in triple-negative breast cancer. <i>Cancer Research</i> , 2014 , 74, 4822-35	10.1	48
215	Locoregional recurrence risk for patients with T1,2 breast cancer with 1-3 positive lymph nodes treated with mastectomy and systemic treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 89, 392-8	4	105
214	High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. <i>PLoS ONE</i> , 2014 , 9, e83113	3.7	65
213	cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. <i>Journal of Cancer</i> , 2014 , 5, 745-53	4.5	32
212	Breast cancer, BRCA mutations, and attitudes regarding pregnancy and preimplantation genetic diagnosis. <i>Oncologist</i> , 2014 , 19, 797-804	5.7	18
211	Gene signature-guided dasatinib therapy in metastatic breast cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 5265-71	12.9	20
210	Outcomes of children exposed in utero to chemotherapy for breast cancer. <i>Breast Cancer Research</i> , 2014 , 16, 500	8.3	48
209	Reverse-phase protein array for prediction of patients at low risk of developing bone metastasis from breast cancer. <i>Oncologist</i> , 2014 , 19, 909-14	5.7	13
208	TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. <i>Molecular Oncology</i> , 2014 , 8, 508-19	7.9	49
207	Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. <i>Clinical Breast Cancer</i> , 2013 , 13, 421-432.e8	3	89
206	Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2. <i>Journal of the National Cancer Institute</i> , 2013 , 105, 654-63	9.7	77
205	Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. <i>Advances in Therapy</i> , 2013 , 30, 870-84	4.1	355
204	Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial. <i>Cancer</i> , 2013 , 119, 1908-15	6.4	70
203	Supplement use during an intergroup clinical trial for breast cancer (S0221). <i>Breast Cancer Research and Treatment</i> , 2013 , 137, 903-13	4.4	16
202	Effect of visceral metastases on the efficacy and safety of everolimus in postmenopausal women with advanced breast cancer: subgroup analysis from the BOLERO-2 study. <i>European Journal of Cancer</i> , 2013 , 49, 2621-32	7.5	48
201	Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. <i>Oncologist</i> , 2013 , 18, 369-76	5.7	54

200	Health-related quality of life and disease symptoms in postmenopausal women with HR(+), HER2(-) advanced breast cancer treated with everolimus plus exemestane versus exemestane monotherapy. <i>Current Medical Research and Opinion</i> , 2013 , 29, 1463-73	2.5	20
199	Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. <i>Clinical Cancer Research</i> , 2013 , 19, 5533-40	12.9	476
198	Incidence, management, and resolution of noninfectious pneumonitis in BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 561-561	2.2	4
197	Correlation of molecular alterations with efficacy of everolimus in hormone receptor positive, HER2-negative advanced breast cancer: Results from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA509-LBA509	2.2	48
196	Correlation of molecular alterations with efficacy of everolimus in hormone-receptor positive (HR+), HER2-negative advanced breast cancer: Preliminary results from BOLERO-2.. <i>Journal of Clinical Oncology</i> , 2013 , 31, LBA509-LBA509	2.2	
195	Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. <i>New England Journal of Medicine</i> , 2012 , 366, 520-9	59.2	2054
194	Combination anastrozole and fulvestrant in metastatic breast cancer. <i>New England Journal of Medicine</i> , 2012 , 367, 435-44	59.2	314
193	Toward individualized breast cancer therapy: translating biological concepts to the bedside. <i>Oncologist</i> , 2012 , 17, 577-84	5.7	14
192	Survival outcomes in HER2-positive invasive lobular breast carcinoma.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 612-612	2.2	1
191	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011 , 13, R67	8.3	161
190	First generation prognostic gene signatures for breast cancer predict both survival and chemotherapy sensitivity and identify overlapping patient populations. <i>Breast Cancer Research and Treatment</i> , 2011 , 130, 155-64	4.4	31
189	Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancer. <i>Journal of the National Cancer Institute</i> , 2011 , 103, 264-72	9.7	175
188	High-dose chemotherapy with autologous stem-cell support as adjuvant therapy in breast cancer: overview of 15 randomized trials. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3214-23	2.2	72
187	Novel staging system for predicting disease-specific survival in patients with breast cancer treated with surgery as the first intervention: time to modify the current American Joint Committee on Cancer staging system. <i>Journal of Clinical Oncology</i> , 2011 , 29, 4654-61	2.2	79
186	Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. <i>Journal of Clinical Oncology</i> , 2011 , 29, 3126-32	2.2	179
185	PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. <i>Molecular Cancer Therapeutics</i> , 2011 , 10, 1093-101	6.1	181
184	Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: a pooled analysis of four randomized trials. <i>Oncologist</i> , 2010 , 15, 476-83	5.7	6
183	Predictors of tumor progression during neoadjuvant chemotherapy in breast cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 1821-8	2.2	110

182	Two good choices to prevent breast cancer: great taste, less filling. <i>Cancer Prevention Research</i> , 2010 , 3, 681-5	3.2	13
181	Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. <i>Journal of Clinical Oncology</i> , 2010 , 28, 92-8	2.2	553
180	Future directions of bone-targeted therapy for metastatic breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 641-51	19.4	85
179	Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. <i>Lancet Oncology</i> , 2010 , 11, 55-65	21.7	1065
178	Molecular predictors of response to trastuzumab and lapatinib in breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2010 , 7, 98-107	19.4	125
177	Analysis of overall survival from a phase III study of ixabepilone plus capecitabine versus capecitabine in patients with MBC resistant to anthracyclines and taxanes. <i>Breast Cancer Research and Treatment</i> , 2010 , 122, 409-18	4.4	59
176	Primary systemic therapy for operable breast cancer patients: the need for the new generation of trial design. <i>Breast Cancer Research and Treatment</i> , 2010 , 124, 701-5	4.4	2
175	A phase 2 study of a fixed combination of uracil and ftorafur (UFT) and leucovorin given orally in a 3-times-daily regimen to treat patients with recurrent metastatic breast cancer. <i>Cancer</i> , 2010 , 116, 1440-5	6.4	4
174	Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer: long-term results from the University of Texas M. D. Anderson Cancer Center Study	6.4	10
173	A phase 2 study of a fixed combination of uracil and ftorafur and leucovorin given orally in a twice-daily regimen to treat patients with recurrent metastatic breast cancer. <i>Cancer</i> , 2010 , 116, 2301-6	6.4	2
172	Circulating tumor cells and biomarkers: implications for personalized targeted treatments for metastatic breast cancer. <i>Breast Journal</i> , 2010 , 16, 327-30	1.2	31
171	Why my neighbor's health is important to me. <i>Oncology</i> , 2010 , 24, 1238	1.8	
170	Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. <i>Cancer Research</i> , 2009 , 69, 4116-24	10.1	674
169	Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3303-11	2.2	126
168	Molecular targets for treatment of inflammatory breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 387-94	19.4	44
167	The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. <i>Oncologist</i> , 2009 , 14, 320-68	5.7	838
166	ERK promotes tumorigenesis by inhibiting FOXO3a via MDM2-mediated degradation. <i>Nature Cell Biology</i> , 2008 , 10, 138-48	23.4	515
165	Using response to primary chemotherapy to select postoperative therapy: long-term results from a prospective phase II trial in locally advanced primary breast cancer. <i>Clinical Breast Cancer</i> , 2008 , 8, 516-21	2.3	10

164	Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 1275-81	2.2	1917
163	Commercialized multigene predictors of clinical outcome for breast cancer. <i>Oncologist</i> , 2008 , 13, 477-93	5.7	210
162	Staging of breast cancer in the neoadjuvant setting. <i>Cancer Research</i> , 2008 , 68, 6477-81	10.1	28
161	A time for creative collaboration. <i>Cancer</i> , 2008 , 113, 2217-20	6.4	2
160	Locally advanced breast cancer: treatment guideline implementation with particular attention to low- and middle-income countries. <i>Cancer</i> , 2008 , 113, 2315-24	6.4	42
159	Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system?. <i>Cancer</i> , 2008 , 113, 2422-30	6.4	137
158	Fingerprinting lymph node metastases. <i>Annals of Surgical Oncology</i> , 2008 , 15, 1275-6	3.1	
157	Circulating Tumor Cells in Metastatic Breast Cancer: Biologic Staging Beyond Tumor Burden. <i>Clinical Breast Cancer</i> , 2007 , 7, 34-42	3	115
156	Inflammatory breast cancer (IBC) and patterns of recurrence: understanding the biology of a unique disease. <i>Cancer</i> , 2007 , 110, 1436-44	6.4	153
155	Clinicopathologic characteristics and prognostic factors in 420 metastatic breast cancer patients with central nervous system metastasis. <i>Cancer</i> , 2007 , 110, 2640-7	6.4	122
154	Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. <i>Journal of Clinical Oncology</i> , 2007 , 25, 2650-5	2.2	215
153	A shortage of oncologists? The American Society of Clinical Oncology workforce study. <i>Journal of Clinical Oncology</i> , 2007 , 25, 1468-9	2.2	62
152	Overall survival and cause-specific mortality of patients with stage T1a,bN0M0 breast carcinoma. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4952-60	2.2	214
151	IKK beta suppression of TSC1 links inflammation and tumor angiogenesis via the mTOR pathway. <i>Cell</i> , 2007 , 130, 440-55	56.2	514
150	Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 2007 , 25, 4414-22	2.2	914
149	Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden. <i>Clinical Breast Cancer</i> , 2007 , 7, 471-9	3	60
148	Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. <i>Cancer</i> , 2006 , 106, 2327-36	6.4	23
147	Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero. <i>Cancer</i> , 2006 , 107, 1219-26	6.4	284

146	Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Journal of Clinical Oncology</i> , 2006 , 24, 4107-15	2.2	295
145	Personalized medicine for breast cancer: moving forward and going back. <i>Personalized Medicine</i> , 2006 , 3, 363-370	2.2	1
144	Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1420-30	2.2	889
143	Moving into the future: treatment of bone metastases and beyond. <i>Cancer Treatment Reviews</i> , 2005 , 31 Suppl 3, 9-18	14.4	13
142	The global breast cancer burden: variations in epidemiology and survival. <i>Clinical Breast Cancer</i> , 2005 , 6, 391-401	3	346
141	The natural history of breast carcinoma in patients with > or = 10 metastatic axillary lymph nodes before and after the advent of adjuvant therapy: a multiinstitutional retrospective study. <i>Cancer</i> , 2005 , 104, 229-35	6.4	22
140	Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. <i>Journal of Clinical Oncology</i> , 2005 , 23, 41-8	2.2	292
139	Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3676-85	2.2	916
138	Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy. <i>Journal of Clinical Oncology</i> , 2005 , 23, 9304-11	2.2	311
137	Chemotherapy: what progress in the last 5 years?. <i>Journal of Clinical Oncology</i> , 2005 , 23, 1760-75	2.2	87
136	The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2294-302	2.2	118
135	Inflammatory breast carcinoma: the sphinx of breast cancer research. <i>Journal of Clinical Oncology</i> , 2004 , 22, 381-3; author reply 383	2.2	29
134	Opportunities and challenges in the development of targeted therapies. <i>Seminars in Oncology</i> , 2004 , 31, 21-7	5.5	27
133	PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. <i>Cancer Cell</i> , 2004 , 6, 117-27	24.3	1462
132	Is breast cancer survival improving?. <i>Cancer</i> , 2004 , 100, 44-52	6.4	410
131	Prognostic value of P53, MDM-2, and MUC-1 for patients with inflammatory breast carcinoma. <i>Cancer</i> , 2004 , 101, 913-7	6.4	17
130	Targeted Radiotherapy to the Skeleton Using ¹⁶⁶ Ho-DOTMP with Autologous Stem Cell Transplantation for Patients with Bone-Only Metastatic Breast Cancer.. <i>Blood</i> , 2004 , 104, 5239-5239	2.2	1
129	New approaches to breast cancer therapy. <i>Breast Cancer Research and Treatment</i> , 2003 , 80 Suppl 1, S1-2; discussion S13-8	4.4	21

128	Future directions in the endocrine therapy of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2003 , 80 Suppl 1, S37-9	4.4	4
127	Novel approaches to the management of bone metastases. <i>Seminars in Oncology</i> , 2003 , 30, 161-6	5.5	7
126	Update on the management of inflammatory breast cancer. <i>Oncologist</i> , 2003 , 8, 141-8	5.7	111
125	The status of breast cancer management: challenges and opportunities. <i>Breast Cancer Research and Treatment</i> , 2002 , 75 Suppl 1, S61-5; discussion S57-9	4.4	9
124	Gemcitabine in combination with vinorelbine for treatment of advanced breast cancer. <i>Clinical Breast Cancer</i> , 2002 , 3 Suppl 1, 34-8	3	7
123	Long-term complications associated with breast-conservation surgery and radiotherapy 2002 , 9, 543		8
122	Novel approaches to the management of bone metastases in patients with breast cancer. <i>Seminars in Oncology</i> , 2002 , 29, 134-44	5.5	35
121	Integration of docetaxel into adjuvant breast cancer treatment regimens. <i>Oncology</i> , 2002 , 16, 27-33	1.8	
120	Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. <i>Pathology and Oncology Research</i> , 2001 , 7, 171-7	2.6	52
119	Phase I study of vinorelbine and paclitaxel by 3-hour simultaneous infusion with and without granulocyte colony-stimulating factor support in metastatic breast carcinoma. <i>Cancer</i> , 2001 , 91, 664-671	6.4	8
118	Breast conservation therapy as a treatment option for the elderly. The M. D. Anderson experience. <i>Cancer</i> , 2001 , 92, 1092-100	6.4	42
117	Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. <i>Cancer</i> , 2001 , 92, 2523-8	6.4	129
116	Phase I-II vinorelbine (Navelbine) by continuous infusion in patients with metastatic breast cancer: cumulative toxicities limit dose escalation. <i>Cancer Investigation</i> , 2001 , 19, 459-66	2.1	7
115	Canalicular stenosis as the underlying mechanism for epiphora in patients receiving weekly docetaxel. <i>Oncologist</i> , 2001 , 6, 551-2	5.7	26
114	Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Center experience. <i>Journal of Clinical Oncology</i> , 2001 , 19, 628-33	2.2	163
113	Progress in systemic chemotherapy of primary breast cancer: an overview. <i>Journal of the National Cancer Institute Monographs</i> , 2001 , 72-9	4.8	34
112	The evolving role of bisphosphonates. <i>Seminars in Oncology</i> , 2001 , 28, 284-290	5.5	17
111	Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. <i>Seminars in Oncology</i> , 2001 , 28, 43-47	5.5	72

110	Female patients with breast carcinoma age 30 years and younger have a poor prognosis 2001 , 92, 2523		1
109	Oral bisphosphonates. <i>Cancer</i> , 2000 , 88, 6-14	6.4	111
108	Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. <i>Cancer</i> , 2000 , 88, 1082-90	6.4	507
107	Combined modality treatment of locally advanced breast carcinoma in elderly patients or patients with severe comorbid conditions using tamoxifen as the primary therapy. <i>Cancer</i> , 2000 , 88, 2054-60	6.4	28
106	Developments in chemotherapy of breast cancer. <i>Cancer</i> , 2000 , 88, 3073-3079	6.4	70
105	Phase II study of paclitaxel in patients with metastatic breast carcinoma refractory to standard chemotherapy. <i>Cancer</i> , 2000 , 89, 2195-201	6.4	16
104	Phase II trial and pharmacokinetic evaluation of cytosine arabinoside for leptomeningeal metastases from breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 382-6	3.5	30
103	Phase I study of liposomal annamycin. <i>Cancer Chemotherapy and Pharmacology</i> , 2000 , 46, 427-32	3.5	11
102	Prognostic implications of pathological lymph node status after preoperative chemotherapy for operable T3N0M0 breast cancer. <i>Annals of Surgical Oncology</i> , 2000 , 7, 435-40	3.1	24
101	Ductal carcinoma-in-situ: long-term results of breast-conserving therapy. <i>Annals of Surgical Oncology</i> , 2000 , 7, 656-64	3.1	32
100	Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. <i>Journal of the National Cancer Institute</i> , 2000 , 92, 225-33	9.7	141
99	Risks and benefits of taxanes in breast and ovarian cancer. <i>Drug Safety</i> , 2000 , 23, 401-28	5.1	84
98	Phase II trial of liposome-encapsulated doxorubicin, cyclophosphamide, and fluorouracil as first-line therapy in patients with metastatic breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 1425-34	2.2	75
97	Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. <i>Journal of Clinical Oncology</i> , 1999 , 17, 3412-7	2.2	207
96	Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. <i>Journal of Clinical Oncology</i> , 1999 , 17, 846-54	2.2	524
95	Management of breast cancer during pregnancy using a standardized protocol. <i>Journal of Clinical Oncology</i> , 1999 , 17, 855-61	2.2	340
94	Phase I/II trial of high dose mitoxantrone in metastatic breast cancer: the M.D. Anderson Cancer Center experience. <i>Breast Cancer Research and Treatment</i> , 1999 , 54, 225-33	4.4	10
93	Relapse after complete response to anthracycline-based combination chemotherapy in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1999 , 55, 1-8	4.4	4

92	Phase II study of mitoxantrone by 14-day continuous infusion with granulocyte colony-stimulating factor (GCSF) support in patients with metastatic breast cancer and limited prior therapy. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 86-91	3.5	2
91	Doxorubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: the M.D. Anderson experience. <i>Cancer Chemotherapy and Pharmacology</i> , 1999 , 43, 471-8	3.5	45
90	Primary tumor response to induction chemotherapy as a predictor of histological status of axillary nodes in operable breast cancer patients. <i>Annals of Surgical Oncology</i> , 1999 , 6, 762-7	3.1	27
89	Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. <i>Cancer</i> , 1999 , 85, 104-11	6.4	103
88	Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma. <i>Cancer</i> , 1999 , 86, 1251-7	6.4	20
87	Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. <i>Journal of Clinical Oncology</i> , 1999 , 17, 460-9	2.2	1058
86	Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol. <i>Oncogene</i> , 1998 , 16, 2087-94	9.2	112
85	Tyrosine kinase inhibitors, emodin and its derivative repress HER-2/neu-induced cellular transformation and metastasis-associated properties. <i>Oncogene</i> , 1998 , 16, 2855-63	9.2	101
84	Hand-foot syndrome following prolonged infusion of high doses of vinorelbine. <i>Cancer</i> , 1998 , 82, 965-9	6.4	37
83	Progress in endocrine therapy for breast carcinoma. <i>Cancer</i> , 1998 , 83, 1-6	6.4	9
82	Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer. <i>Annals of Surgical Oncology</i> , 1998 , 5, 673-80	3.1	64
81	New antiestrogens in breast cancer: a review. <i>Breast Journal</i> , 1998 , 4, 213-29	1.2	2
80	Residual metastatic axillary lymph nodes following neoadjuvant chemotherapy predict disease-free survival in patients with locally advanced breast cancer. <i>American Journal of Surgery</i> , 1998 , 176, 502-9	2.7	132
79	Treatment of breast cancer. <i>New England Journal of Medicine</i> , 1998 , 339, 974-84	59.2	576
78	Anastrozole (Arimidex), a new aromatase inhibitor for advanced breast cancer: mechanism of action and role in management. <i>Cancer Investigation</i> , 1998 , 16, 385-90	2.1	5
77	Integration of Systemic Chemotherapy in the Management of Primary Breast Cancer. <i>Oncologist</i> , 1998 , 3, 300-313	5.7	11
76	Paclitaxel-induced pancreatitis: a case report. <i>Journal of the National Cancer Institute</i> , 1997 , 89, 91-3	9.7	15
75	The tumor suppression activity of E1A in HER-2/neu-overexpressing breast cancer. <i>Oncogene</i> , 1997 , 14, 561-8	9.2	76

74	Anthracycline-Resistant Breast Cancer. <i>Breast Cancer</i> , 1997 , 4, 221-227	3.4	2
73	Combined-modality treatment of inflammatory breast carcinoma: twenty years of experience at M. D. Anderson Cancer Center. <i>Cancer Chemotherapy and Pharmacology</i> , 1997 , 40, 321-9	3.5	203
72	Chemotherapy-induced neutropenia and fever in patients with metastatic breast carcinoma receiving salvage chemotherapy. <i>Cancer</i> , 1997 , 79, 1150-7	6.4	31
71	The prognostic significance of sialyl-Tn antigen in women treated with breast carcinoma treated with adjuvant chemotherapy. <i>Cancer</i> , 1997 , 80, 2240-9	6.4	35
70	Secondary drug resistance in breast cancer: failure to reverse with oral nifedipine. <i>International Journal of Cancer</i> , 1997 , 73, 184-6	7.5	4
69	A phase II study of CI-973 [SP-4-3(R)]-1,1-cyclobutane-dicarboxylato (2-)] (2-methyl-1,4-butanediamine-N, N ϕ)platinum in patients with refractory advanced breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1996 , 38, 289-91	3.5	8
68	Technical approach for the study of the genetic evolution of breast cancer from paraffin-embedded tissue sections. <i>Breast Cancer Research and Treatment</i> , 1996 , 39, 177-85	4.4	11
67	Locally Advanced Breast Cancer. <i>Oncologist</i> , 1996 , 1, 8-17	5.7	53
66	Current status of adjuvant systemic therapy for primary breast cancer: progress and controversy. <i>Ca-A Cancer Journal for Clinicians</i> , 1995 , 45, 199-226	220.7	46
65	Factors predicting long-term survival for metastatic breast cancer patients treated with high-dose chemotherapy and bone marrow support. <i>Cancer</i> , 1994 , 73, 2157-67	6.4	86
64	Multidisciplinary management of advanced primary and metastatic breast cancer. <i>Cancer</i> , 1994 , 74, 416-23	8.4	97
63	Phase I trial of droloxifene in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 313-6	3.5	28
62	Anthracycline antibiotics in cancer therapy. Focus on drug resistance. <i>Drugs</i> , 1994 , 47, 223-58	12.1	144
61	Phase I trial of droloxifene in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1994 , 33, 313-316	3.5	
60	Present status of anthracyclines in the adjuvant treatment of breast cancer. <i>Drugs</i> , 1993 , 45 Suppl 2, 10-9; discussion 18-9	12.1	19
59	The order of administration of chemotherapy and radiation and its effect on the local control of operable breast cancer. <i>Cancer</i> , 1993 , 71, 3680-4	6.4	54
58	Strategies for the application of biomarkers for risk assessment and efficacy in breast cancer chemoprevention trials. <i>Journal of Cellular Biochemistry</i> , 1993 , 17G, 37-43	4.7	6
57	Complications associated with indwelling catheters. <i>Medical and Pediatric Oncology</i> , 1992 , 20, 22-5		11

56	Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. <i>Cancer</i> , 1992 , 69, 448-52	6.4	58
55	A randomized trial of two dosage schedules of mitomycin C in advanced breast carcinoma. <i>Cancer</i> , 1992 , 69, 476-81	6.4	19
54	Feasibility of breast-conservation surgery after induction chemotherapy for locally advanced breast carcinoma. <i>Cancer</i> , 1992 , 69, 2849-52	6.4	210
53	Ki-67 immunostaining in node-negative stage I/II breast carcinoma. Significant correlation with prognosis. <i>Cancer</i> , 1991 , 68, 549-57	6.4	147
52	Radiotherapy enhances the toxicity of aminoglutethimide. <i>Medical and Pediatric Oncology</i> , 1990 , 18, 162-4		1
51	Is chemotherapy effective in reducing the local failure rate in patients with operable breast cancer?. <i>Cancer</i> , 1990 , 65, 394-9	6.4	50
50	Pregnancy and offspring after adjuvant chemotherapy in breast cancer patients. <i>Cancer</i> , 1990 , 65, 847-50	6.4	107
49	Trilostane with hydrocortisone in treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1989 , 13, 117-21	4.4	9
48	Ductal carcinoma-in-situ of the breast: fine-needle aspiration cytology of 12 cases. <i>Diagnostic Cytopathology</i> , 1989 , 5, 371-7	1.4	29
47	The role of serum CEA as a prognostic indicator in stage II and III breast cancer patients treated with adjuvant chemotherapy. <i>Cancer</i> , 1989 , 63, 828-35	6.4	20
46	5-Fluorouracil rechallenge by protracted infusion in refractory breast cancer. <i>Cancer</i> , 1989 , 64, 793-7	6.4	45
45	Sequential cyclic combined hormonal therapy for metastatic breast cancer. <i>Cancer</i> , 1989 , 64, 1002-6	6.4	11
44	Role of adjuvant chemotherapy in male breast cancer. <i>Cancer</i> , 1989 , 64, 1583-5	6.4	102
43	Angiosarcoma arising in an irradiated breast. A case report and review of the literature. <i>Cancer</i> , 1989 , 64, 2214-6	6.4	60
42	Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1989 , 12, 123-8	2.7	63
41	Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. <i>Cancer</i> , 1988 , 62, 2098-104	6.4	22
40	Sequential multiagent chemotherapy incorporating cisplatin, doxorubicin, and cyclophosphamide in the treatment of metastatic breast cancer. <i>Cancer</i> , 1988 , 62, 2105-10	6.4	5
39	Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. <i>Cancer</i> , 1988 , 62, 2507-16	6.4	415

38	Mitoxantrone, cyclophosphamide, and fluorouracil in metastatic breast cancer unresponsive to hormonal therapy. <i>Cancer</i> , 1987 , 59, 1992-9	6.4	10
37	Chemotherapy with mitoxantrone in combination with continuous infusion vinblastine for metastatic breast cancer. <i>Cancer</i> , 1987 , 60, 1724-8	6.4	2
36	Combined antiestrogen and cytotoxic therapy with pseudomonas vaccine immunotherapy for metastatic breast cancer. A prospective, randomized trial. <i>Cancer</i> , 1987 , 60, 2596-604	6.4	11
35	Trioxifene mesylate in the treatment of advanced breast cancer. <i>Cancer</i> , 1986 , 57, 40-3	6.4	20
34	Clinical course of breast cancer patients with osseous metastasis treated with combination chemotherapy. <i>Cancer</i> , 1986 , 58, 2589-93	6.4	99
33	A comparative study of bisantrene given by two dose schedules in patients with metastatic breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1986 , 18, 157-61	3.5	2
32	Oral medroxyprogesterone acetate in the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 1985 , 5, 321-6	4.4	40
31	Regulation of breast tumor growth by high dose estrogen is independent of the presence of estrogen receptors. <i>Breast Cancer Research and Treatment</i> , 1985 , 6, 237-40	4.4	8
30	A comparative randomized trial of vinca alkaloids in patients with metastatic breast carcinoma. <i>Cancer</i> , 1985 , 55, 337-40	6.4	36
29	Improved survival of patients with metastatic breast cancer receiving combination chemotherapy. <i>Cancer</i> , 1985 , 55, 341-6	6.4	71
28	Five-day continuous-infusion vinblastine in the treatment of breast cancer. <i>Cancer</i> , 1985 , 56, 225-9	6.4	42
27	A comparative study of PALA, PALA plus 5-FU, and 5-FU in advanced breast cancer. <i>Cancer</i> , 1985 , 56, 1320-4	6.4	9
26	Doxorubicin-induced congestive heart failure in adults. <i>Cancer</i> , 1985 , 56, 1361-5	6.4	101
25	Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. <i>Cancer</i> , 1984 , 53, 384-9	6.4	64
24	Tumor-associated fever in breast cancer. <i>Cancer</i> , 1984 , 53, 1596-9	6.4	12
23	Combination chemotherapy of metastatic breast carcinoma with cyclophosphamide, adriamycin, and peptichemio. <i>Cancer</i> , 1984 , 53, 1836-40	6.4	4
22	Combination chemotherapy for metastatic breast cancer with fluorouracil, adriamycin, cyclophosphamide, and methotrexate. <i>Journal of Surgical Oncology</i> , 1984 , 26, 205-7	2.8	1
21	Analysis of the Antitumor Agent Bay i 7433 (Copovithane) in Plasma and Urine by High Performance Liquid Chromatography. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1984 , 7, 159-166		1

20	Response of metastatic breast cancer to tamoxifen withdrawal: report of a case. <i>Journal of Surgical Oncology</i> , 1983 , 22, 45-6	2.8	23
19	Spontaneous regression of breast carcinoma: follow-up report and literature review. <i>Journal of Surgical Oncology</i> , 1982 , 19, 22-4	2.8	13
18	Peptichemio versus melphalan (L-PAM) in advanced breast cancer. <i>Cancer</i> , 1982 , 49, 1767-70	6.4	4
17	Treatment for meningeal carcinomatosis in breast cancer. <i>Cancer</i> , 1982 , 50, 219-22	6.4	83
16	Management of inflammatory carcinoma of breast with combined modality approach - an update. <i>Cancer</i> , 1981 , 47, 2537-42	6.4	56
15	Management of breast cancer patients failing adjuvant chemotherapy with adriamycin-containing regimens. <i>Cancer</i> , 1981 , 47, 2798-802	6.4	62
14	Combination chemotherapy for breast cancer metastatic to bone marrow. <i>Cancer</i> , 1981 , 48, 227-32	6.4	8
13	Response to hormonal therapy as a prognostic factor for metastatic breast cancer treated with combination chemotherapy. <i>Cancer</i> , 1980 , 46, 438-45	6.4	19
12	Combined chemoimmunotherapy for advanced breast cancer: a comparison of BCG and levamisole. <i>Cancer</i> , 1979 , 43, 1112-22	6.4	29
11	Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. <i>Cancer</i> , 1979 , 43, 1225-33	6.4	49
10	Bone marrow metastases without cortical bone involvement in breast cancer patients. <i>Cancer</i> , 1979 , 44, 196-8	6.4	21
9	Combination chemotherapy with vincristine and methotrexate for advanced refractory breast cancer. <i>Cancer</i> , 1979 , 44, 32-4	6.4	6
8	Ftorafur, adriamycin, cyclophosphamide and BCG in the treatment of metastatic breast cancer. <i>Cancer</i> , 1979 , 44, 398-405	6.4	17
7	The natural history of breast cancer patients with brain metastases. <i>Cancer</i> , 1979 , 44, 1913-8	6.4	249
6	Combination chemoimmunotherapy of metastatic breast cancer with 5-fluorouracil, adriamycin, cyclophosphamide, and BCG. <i>Cancer</i> , 1979 , 44, 1955-62	6.4	25
5	Combined chemoimmunotherapy and radiation therapy of inflammatory breast carcinoma. <i>Journal of Surgical Oncology</i> , 1979 , 11, 325-32	2.8	29
4	Adjuvant chemoimmunotherapy following regional therapy for isolated recurrences of breast cancer (stage IV NED). <i>Journal of Surgical Oncology</i> , 1979 , 12, 27-40	2.8	43
3	Chemoimmunotherapy with or without oophorectomy in premenopausal patients with advanced breast cancer. <i>Journal of Surgical Oncology</i> , 1979 , 12, 333-41	2.8	1

2	Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. <i>Cancer</i> , 1978 , 41, 1064-75	6.4	55
1	Adriamycin and 1-(2-chlorethyl)-3-cyclohexyl-1-nitrosourea (CCNU) in the treatment of metastatic breast cancer. <i>Cancer</i> , 1978 , 41, 1235-9	6.4	14